Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms anti-CD3/anti-FOLR-1 bispecific T-cell engager (Amgen) |
Target |
Action stimulants, modulators |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), FOLR1 modulators(Folate receptor alpha modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Preclinical | Germany | - | |
Ovarian Cancer | Preclinical | United States | - |